C
Conmed
A global medical technology company that specializes in the development and sale of surgical and patient monitoring products and services
About Conmed
Conmed Corporation was founded in 1970 by Eugene Corasanti, a visionary entrepreneur with a keen interest in advancing medical technology. The company initially focused on developing and manufacturing medical devices that would improve surgical outcomes and patient care. Corasanti's leadership and vision were instrumental in steering the company through its formative years.
In 1987, Conmed took a significant step forward by going public through an initial public offering on the NASDAQ exchange. This move not only provided the company with the capital needed to expand its operations but also increased its visibility in the competitive medical technology industry.
Over the years, Conmed has grown through strategic acquisitions and continuous innovation in surgical and patient monitoring products. These efforts have solidified its position as a key player in the global medical technology market.
Today, Conmed continues to build on its legacy of innovation, focusing on developing cutting-edge medical devices that enhance the quality of healthcare worldwide. The company's journey from a small startup to a publicly traded corporation is a testament to its enduring commitment to improving medical outcomes through technology.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1970
- Headquarters
- Largo, United States
- Listing
- IPO 1987
- Employees
- 3,425
- Open positions
- None listed
- Dealroom signal
- 45.3/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, observatoire healthtech
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 3 companies, latest Aug 2022
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Jun 2026 | $450M | — | Undisclosed | ↗ |
| POST IPO DEBT✓Debt | Jun 2025 | $550M | — | JPMorgan Chase & Co | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Conmed is 38K monthly website visits, up 58.3% over the last three months. Conmed's team grew 24.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
BiorezNew Haven, United StatesDeveloping and commercializing regenerative implants related to the orthopedic surgery
$14Mvaluation
In2BonesMemphis, United StatesInnovative french company specialising in the design and manufacture of medical devices intended for use in surgery
$145Mvaluation
SurgiQuestOrange, United StatesSurgiQuest - Medical Device Company - AirSeal - AnchorPort
$265Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
JPMorgan Chase & Co
Other known investors1 additional known investor
Hudson River Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Conmed on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Conmed’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.